Quick Answer
AN2 Therapeutics, Inc. reported Diluted EPS of $1.16 per share (loss) for fiscal year 2025.
AN2 Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.16 | +32.6% |
| 2024 | -$1.72 | +37.2% |
| 2023 | -$2.74 | +1.8% |
| 2022 | -$2.79 | +73.8% |
| 2021 | -$10.64 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.31 | +27.9% | -47.6% |
| June 30, 2025 | -$0.21 | +56.3% | +40.0% |
| March 31, 2025 | -$0.35 | +37.5% | +18.6% |
| September 30, 2024 | -$0.43 | +33.8% | +10.4% |
| June 30, 2024 | -$0.48 | +40.7% | +14.3% |
| March 31, 2024 | -$0.56 | +29.1% | +13.8% |
| September 30, 2023 | -$0.65 | -10.2% | +19.8% |
| June 30, 2023 | -$0.81 | -52.8% | -2.5% |
- AN2 Therapeutics, Inc. showed an increase of +32.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, AN2 Therapeutics, Inc.’s diluted eps has grown by 89.1% (from $10.64 per share (loss) to $1.16 per share (loss)).
- The most recent figure is from AN2 Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: